Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union

Fresenius Kabi announced today the launch of its tocilizumab biosimilar Tyenne^® referencing RoActemra^®** (tocilizumab) in the European Union. 

Tyenne^® becomes the first tocilizumab biosimilar available in Europe for the treatment of several inflammatory and immune diseases.

Tyenne^® is Fresenius Kabi’s third approved biosimilar launched in Europe, offering patients and heath care providers a flexible range of user-friendly subcutaneous (prefilled syringe and autoinjector) and intravenous (vials) administration. 

* Tyenne^® (tocilizumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries. 
** RoActemra^® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.